IVIG is given intravenously (IV) usually over two days in a row, once a month. Therapy is recommended for at least 6 months before deciding if it should be continued. This is a mutual decision made between you and your physician. A nurse inserts a small IV catheter into a vein on your hand or arm. The first dose is administered in the physician's office. This is done to observe for any possible reactions to the medication.

Antibodies only survive for 3 to 4 weeks. Infusions are administered every 3 to 4 weeks so you can maintain adequate immunoglobulin levels in your blood.

IVIG is a treatment for many immune disorders. Preliminary research suggests that it may help maintain pregnancy in women who have experienced secondary recurrent miscarriage by improving the mother’s immune response to this pregnancy. Currently, Dr. Stephenson is conducting an international trial to test whether IVIG helps promote successful pregnancies in women who have suffered secondary recurrent miscarriage.

IVIG has been shown to be beneficial in the treatment of several immune regulation disorders. Extensive evidence exists suggesting that immunoregulatory mechanisms are involved in MS. Several possible mechanisms by which IVIG improves the course of the disease are related to limiting the inflammatory process and repairing the damage to the myelin sheath by enhancing remyelination. Presently, the evidence through research supports that IVIG is beneficial for patients with MS.

It is made from human blood that is chemically treated using a process that filters and removes contaminants (i.e., bacteria and viruses). It is then purified and lyophilized ("freeze-dried") and then bottled. The final product is a white to pale yellow powder that is reconstituted with sterile water prior to infusion. In 1993 -1994 there were a number of reported cases of Hepatitis C that were thought to be caused by a contaminated lot of IVIG.

IVIG is an expensive therapy which has been used to treat a number of neurological diseases. At the present time, it is not approved by the FDA for treatment of MS although widely used. Recent clinical trials have provided strong evidence of the clinical benefit to MS patients using IVIG. Most insurance companies will pay for IVIG for patients with relapsing-remitting MS. A letter from your physician outlining your medical history and response to other therapies is usually required.

IVIG Indications & Clinical Benefits | Overview of Multiple Sclerosis | Recent Medical Literature | FAQ

MedPro Rx will deliver all IVIg and related supplies directly to your site of service be it in the home, physician’s office or infusion clinic. We deliver anywhere in the United States. Your orders will be delivered via Federal Express, UPS or local courier. We do not charge delivery fees.

The smallpox vaccine is not given with a hypodermic needle. It is not a “shot,” like many vaccinations. The vaccine is given using a bifurcated (two-pronged) needle that is dipped into the vaccine solution. When removed, the needle retains a droplet of the vaccine. The needle is then used to quickly prick the skin several times for a few seconds. The pricking is not deep, but it will cause a sore spot and one or two drops of blood to form. The vaccine usually is given in the upper arm.

RITUXAN® (Rituximab) in combination with methotrexate is indicated to reduce signs and symptoms in adult patients with moderately- to severely- active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies.

Rituxan is given as an intravenous (IV) infusion, along with methotrexate. One course of treatment requires 2 separate IV infusions given 2 weeks apart. Each infusion will be given by a healthcare professional at your doctor's office, an infusion center, or a hospital. Before each infusion, you may be given additional medicine, including glucocorticoids, to reduce possible side effects.

No. This is a painless non-invasive procedure. Electrodes will be applied to the scalp using a conductive gel and gauze. Sensors attached to the face, torso and legs will be secured using adhesive tape and tabs.

Chemotherapy is usually given on an outpatient basis. The medication is administered through a vein in your arm. A specially trained nurse remains with you at all times while your chemotherapy is infusing. You may receive other medications before and during your chemotherapy which are designed to minimize and relieve side effects. There are several chemotherapy medications that work to kill lung cancer and often a combination of two of these medications is prescribed.

A simple acute problem, such as a muscle sprain, may require only one treatment, whereas more severe or chronic ailments may need a dozen treatments. When multiple treatments are necessary, they usually begin intensively. Patients often start with 1-3 treatments per week for 4-6 weeks. A positive response is usually seen after the first to third treatment. Once a maximum positive response is achieved treatments are usually tapered off.

Frequent oral exams are given in most classes, and written mid-term and final examinations are given in all courses. Students who don't pass a final exam on the first try are given two more weeks to study and get additional tutoring, and then can retake the exam. (This second try is called the "extraordinario.") Students who don't pass the extraordinario are able to retake the exam one more time in early August. (The third try is called the "mundial.

XOLAIR is given through subcutaneous injection, which means it is injected just under the skin. XOLAIR should always be injected in a doctor's office.

You will receive XOLAIR once every 2 or 4 weeks. Your dose will be determined by your IgE level, which your doctor will measure with a simple blood test, and your body weight. Based on your dose, your doctor will also tell you if you will need 1, 2, or 3 injections per dose. If you need more than 1 injection, each will be given in a different place on your body.

Once your test is processed, you can call in to find out your test result. You retrieve your results by calling the toll-free number included in your test kit. If you are transferred to a counselor, there is no reason to panic, this does not automatically mean that you have tested positive.

Signals are given by the system as soon as it decides to open a new position or exit the current one. Those positions taken by the system are only assumed on the beginning of each hour. At that moment, the pages containing the system's signals on the restricted area will be updated, as well as emails will be sent to the system's subscribers on the same minute that the order is assumed.

In most states/territories, IVIg is ordered from TMS (Transfusion Medicine Services) at the ARCBS. Distribution procedures from the ARCBS vary slightly between jurisdictions, but this will not change as a result of the introduction of the Criteria.

IVIg products used in Australia, whether locally produced or imported, must be assessed and approved by the Therapeutic Goods Administration (TGA). The TGA regulates the safety, quality and efficacy of IVIg products. Four overseas manufactured IVIg products have been approved and registered for use in Australia. Two of these (Sandoglobulin ® and Octagam ®) are presently used to supplement supplies of the domestic product (Intragam ®P). Yes.

Information about IVIg products is available at www.nba.gov.au and www.transfusion.com.au and also at the websites of the pharmaceutical companies www.csl.com.au and www.octapharma.com The Criteria for the Clinical Use of Intravenous Immunoglobulin (IVIg) in Australia has been developed to assist clinicians and transfusion medicine professionals to identify the conditions and circumstances for which the use of intravenous immunoglobulin (IVIg) is appropriate. Read more

Vivaglobin? is prepared using the same rigorous donor selection and testing processes that are used in the manufacturing of IVIg. The manufacturing procedure for Vivaglobin? includes multiple processing steps that reduce the risk of virus transmission. The virus reduction capacity of the two steps has been evaluated in a series of in vitro spiking experiments; the steps were alcohol/pH precipitation and pasteurization in aqueous solution at 60o C for 10 hours.

Vivaglobin? was shown to be as effective as IVIg in two prospective studies, one in the US and Canada, the other a non-IND study in Europe and Brazil. The North American (NA) Phase 2/3 study was designed to include open-label, prospective, multicenter trials with 3 sites in Canada and 16 sites in the US. The pharmacokinetics (PK) were measured to compare the area under the curve (AUC) of IVIg with that of Vivaglobin?. The subjects in the PK study were then assessed and doses adjusted.

It is recommended that the patient start treatment with Vivaglobin? one week after receiving a regularly scheduled IVIg infusion. The initial weekly Vivaglobin? dose can be calculated by multiplying the previous IVIg dose by 1.37, then dividing this dose into weekly doses based on the patient's previous IVIg treatment interval; for example, if IVIg was administered every three weeks, divide by 3.

When IVIg can not be accessed under the National arrangements, if the clinician considers that the patient would benefit from IVIg therapy, the clinician may still obtain IVIg through the Jurisdictional Direct Order (JDO) provision. Note that procedures for accessing IVIg JDO arrangements will vary and only imported IVIg is available under JDO arrangements.